SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
SciSparc Ltd. (SPRC) and Clearmind Medicine Inc. (CMND) announced the publication of a European patent application for their combination therapy targeting cocaine addiction. The treatment combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's Palmitoylethanolamide.
The patent is based on preclinical trials conducted at Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their natural reward responses, suggesting its specificity in targeting drug-related compulsions. This European patent application adds to existing applications filed in the U.S. and other global territories.
SciSparc Ltd. (SPRC) e Clearmind Medicine Inc. (CMND) hanno annunciato la pubblicazione di una domanda di brevetto europea per la loro terapia combinata contro la dipendenza da cocaina. Il trattamento unisce il MEAI (5-metossi-2-aminoindano) di Clearmind con la Palmitoiletanolamide di SciSparc.
Il brevetto si basa su studi preclinici condotti presso il Gonda Multidisciplinary Brain Research Center dell'Università Bar-Ilan. La ricerca ha dimostrato che il MEAI riduce significativamente il comportamento di ricerca della cocaina negli animali senza influenzare le risposte ai premi naturali, suggerendo una specificità nel mirare alle compulsioni legate alla droga. Questa domanda di brevetto europea si aggiunge a quelle già depositate negli Stati Uniti e in altri territori globali.
SciSparc Ltd. (SPRC) y Clearmind Medicine Inc. (CMND) anunciaron la publicación de una solicitud de patente europea para su terapia combinada dirigida a la adicción a la cocaína. El tratamiento combina el MEAI (5-metoxi-2-aminoindano) de Clearmind con la Palmitoiletanolamida de SciSparc.
La patente se basa en ensayos preclínicos realizados en el Centro Multidisciplinario de Investigación Cerebral Gonda de la Universidad Bar-Ilan. La investigación demostró que el MEAI reduce significativamente el comportamiento de búsqueda de cocaína en animales sin afectar sus respuestas a recompensas naturales, lo que sugiere su especificidad para atacar las compulsiones relacionadas con las drogas. Esta solicitud de patente europea se suma a las ya presentadas en EE. UU. y otros territorios a nivel mundial.
SciSparc Ltd. (SPRC)와 Clearmind Medicine Inc. (CMND)가 코카인 중독을 목표로 하는 병용 치료법에 대한 유럽 특허 출원 발표를 했습니다. 이 치료법은 Clearmind의 MEAI(5-메톡시-2-아미노인단)와 SciSparc의 팔미토일에탄올아마이드를 결합한 것입니다.
이 특허는 바르일란 대학교 곤다 다학제 뇌 연구 센터에서 수행된 전임상 시험을 기반으로 합니다. 연구 결과 MEAI는 동물의 코카인 탐색 행동을 현저히 감소시키면서도 자연 보상 반응에는 영향을 미치지 않아, 약물 관련 강박 행동을 특정적으로 겨냥함을 시사합니다. 이 유럽 특허 출원은 미국 및 기타 글로벌 지역에서 이미 출원된 특허에 추가됩니다.
SciSparc Ltd. (SPRC) et Clearmind Medicine Inc. (CMND) ont annoncé la publication d'une demande de brevet européenne pour leur thérapie combinée ciblant la dépendance à la cocaïne. Le traitement associe le MEAI (5-méthoxy-2-aminoindane) de Clearmind à la Palmitoyléthanolamide de SciSparc.
Le brevet repose sur des essais précliniques réalisés au Centre de Recherche Multidisciplinaire sur le Cerveau Gonda de l'Université Bar-Ilan. La recherche a démontré que le MEAI réduisait significativement le comportement de recherche de cocaïne chez les animaux sans affecter leurs réponses aux récompenses naturelles, suggérant une spécificité dans le ciblage des compulsions liées à la drogue. Cette demande de brevet européenne s'ajoute à celles déjà déposées aux États-Unis et dans d'autres territoires mondiaux.
SciSparc Ltd. (SPRC) und Clearmind Medicine Inc. (CMND) haben die Veröffentlichung einer europäischen Patentanmeldung für ihre Kombinationstherapie gegen Kokainabhängigkeit bekanntgegeben. Die Behandlung kombiniert Clearminds MEAI (5-Methoxy-2-aminoindan) mit SciSparcs Palmitoylethanolamid.
Das Patent basiert auf präklinischen Studien, die am Gonda Multidisziplinären Hirnforschungszentrum der Bar-Ilan-Universität durchgeführt wurden. Die Forschung zeigte, dass MEAI das kokainbezogene Suchverhalten bei Tieren signifikant reduzierte, ohne deren natürliche Belohnungsreaktionen zu beeinflussen, was auf eine Spezifität bei der Bekämpfung von drogenbezogenen Zwängen hindeutet. Diese europäische Patentanmeldung ergänzt bereits bestehende Anmeldungen in den USA und weiteren globalen Regionen.
- Patent application published by European Patent Office for novel cocaine addiction treatment
- Preclinical trials showed significant reduction in cocaine-induced craving
- Treatment specifically targets drug-related compulsions without affecting natural reward responses
- Multiple patent applications already filed in U.S. and other global territories
- Treatment still in preclinical stage, requiring extensive further testing
- No human trial data available yet
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a European patent application by the European Patent Office. The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These results followed an earlier trial in which animals treated with MEAI exhibited a significant reduction in cocaine-induced craving.
Building on these findings, further research assessed whether MEAI’s effect on drug-seeking behavior extends to natural rewards, as reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards, such as sucrose. This suggests that MEAI’s effect on drug craving is not linked to the general reward system but rather specifically targets drug-related compulsions.
This latest publication adds to multiple patent applications already filed in the U.S. and other global territories as part of the ongoing SciSparc-Clearmind collaboration.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY)
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential effect of MEAI on drug craving . Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the new SPRC patent application for cocaine addiction treatment?
What were the key findings of SPRC's preclinical trials for cocaine addiction treatment?
Where has SciSparc filed patent applications for its cocaine addiction treatment?
Who conducted the preclinical trials for SPRC's cocaine addiction treatment?
